[{"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-001", "question": "A 54-year-old man with decompensated alcoholic cirrhosis (MELD-Na 29) is intubated for acute variceal hemorrhage and started on norepinephrine for hemorrhagic shock. Despite volume resuscitation, blood products, and endoscopic band ligation, he requires increasing vasopressor doses. Continuous renal replacement therapy is initiated for worsening azotemia and hyperkalemia. His MAP is 62 mm Hg on norepinephrine 0.24 mcg/kg/min and vasopressin 0.03 units/min. Lactate is 5.1 mmol/L; pH 7.28; ScvO2 76%. Bedside echo shows hyperdynamic LV function, small underfilled LV, and collapsible IVC. CVP is 4 mm Hg. You are considering adding a third agent. Which vasopressor strategy is most appropriate now?", "options": ["Add epinephrine infusion targeting higher MAP (70-75 mm Hg)", "Add low-dose dobutamine to improve splanchnic perfusion", "Add angiotensin II infusion while maintaining current MAP target", "Increase vasopressin above 0.04 units/min to exploit V1 receptor effect", "Switch norepinephrine to phenylephrine to minimize beta-adrenergic effects"], "answer": "C", "answer_index": 2, "explanation": "He has vasodilatory shock in advanced cirrhosis with catecholamine-resistant hypotension despite adequate volume; angiotensin II is reasonable as a third-line agent in catecholamine-refractory vasodilatory shock and has emerging use in hepatorenal-type circulatory failure. Epinephrine would increase lactate and myocardial oxygen demand without addressing RAAS dysregulation; high-dose vasopressin increases ischemia risk, phenylephrine may worsen gut perfusion, and dobutamine is not indicated with hyperdynamic LV and adequate ScvO2.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity: No answer defensible (N). \\nVerdict: No defensible answer. \\nThe clinical vignette describes a patient with acute variceal hemorrhage and shock. Crucially, the bedside echo reveals a \\\"small underfilled LV\\\" and \\\"collapsible IVC\\\" with a CVP of 4 mm Hg. These are definitive signs of significant hypovolemia (preload dependence). The standard of care for a patient with hemorrhagic shock and echocardiographic evidence of hypovolemia is aggressive volume resuscitation (blood products/albumin), not the initiation of a third vasopressor. Adding a pure vasoconstrictor (like Angiotensin II) to an underfilled ventricle increases afterload without addressing the preload deficit, potentially reducing cardiac output and worsening perfusion. While Angiotensin II is a valid third-line agent for refractory *distributive* (vasodilatory) shock, the stem explicitly provides evidence of *hypovolemic* physiology. The premise of the question—choosing a third pressor—contradicts the clinical data requiring volume expansion. Therefore, no option is medically appropriate. \\nMinimal Fix: Change the echo findings to \\\"plump IVC with minimal respiratory variation\\\" or \\\"adequate LV filling\\\" to establish a state of refractory vasodilatory shock where a third pressor would be indicated.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: No answer defensible (N). \nVerdict: No defensible answer. \nThe clinical vignette describes a patient with acute variceal hemorrhage and shock. Crucially, the bedside echo reveals a \"small underfilled LV\" and \"collapsible IVC\" with a CVP of 4 mm Hg. These are definitive signs of significant hypovolemia (preload dependence). The standard of care for a patient with hemorrhagic shock and echocardiographic evidence of hypovolemia is aggressive volume resuscitation (blood products/albumin), not the initiation of a third vasopressor. Adding a pure vasoconstrictor (like Angiotensin II) to an underfilled ventricle increases afterload without addressing the preload deficit, potentially reducing cardiac output and worsening perfusion. While Angiotensin II is a valid third-line agent for refractory *distributive* (vasodilatory) shock, the stem explicitly provides evidence of *hypovolemic* physiology. The premise of the question—choosing a third pressor—contradicts the clinical data requiring volume expansion. Therefore, no option is medically appropriate. \nMinimal Fix: Change the echo findings to \"plump IVC with minimal respiratory variation\" or \"adequate LV filling\" to establish a state of refractory vasodilatory shock where a third pressor would be indicated.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-002", "question": "A 63-year-old woman with a history of JAK2-positive polycythemia vera treated with hydroxyurea for 9 years presents with 3 months of progressive fatigue, 7-kg weight loss, early satiety, and drenching night sweats. Exam shows marked splenomegaly 12 cm below the costal margin. CBC: Hgb 9.1 g/dL, MCV 96 fL, WBC 18,000/µL with left shift, platelets 110,000/µL. Peripheral smear reveals tear-drop cells, nucleated RBCs, and leukoerythroblastosis. LDH is elevated; uric acid is high. Bone marrow aspirate is 'dry'; core biopsy shows hypercellular marrow with grade 3 reticulin fibrosis and atypical megakaryocytic clusters. Cytogenetics: new complex karyotype with monosomy 7. Which is the most appropriate next step in disease-directed management?", "options": ["Escalate hydroxyurea dose and add low-dose aspirin", "Start ruxolitinib and defer further planning until spleen size stabilizes", "Proceed to allogeneic hematopoietic stem cell transplantation evaluation", "Begin azacitidine as first-line therapy for post-PV myelofibrosis", "Initiate weekly pegylated interferon alfa-2a for cytoreduction"], "answer": "C", "answer_index": 2, "explanation": "She has post-polycythemia vera myelofibrosis with symptomatic splenomegaly, cytopenias, leukoerythroblastosis, and high-risk features (complex karyotype, monosomy 7), making allogeneic stem cell transplantation the only curative option and the preferred strategy if eligible. Ruxolitinib improves symptoms and spleen size but is not curative; azacitidine and interferon are not standard first-line disease-modifying therapies in high-risk post-PV MF, and hydroxyurea escalation will not address progression.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The patient has Post-Polycythemia Vera Myelofibrosis. She falls into a High-Risk category (DIPSS/MIPSS70) due to constitutional symptoms, anemia (Hgb < 10 g/dL), and particularly high-risk cytogenetics (complex karyotype, monosomy 7). For a 63-year-old patient with high-risk disease, allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative option and the standard of care recommendation. While JAK inhibitors like ruxolitinib (Option B) are standard for managing splenomegaly and symptoms, Option B is incorrect because it explicitly suggests 'deferring further planning' until stabilization. In high-risk disease with adverse genetics, delaying transplant evaluation is clinically inappropriate. Option A is incorrect as the patient progressed on hydroxyurea and has anemia. Options D and E are not standard first-line management for this presentation. Therefore, Option C (transplant evaluation) is the unique best answer. The question is logically sound and medically accurate.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The patient has Post-Polycythemia Vera Myelofibrosis. She falls into a High-Risk category (DIPSS/MIPSS70) due to constitutional symptoms, anemia (Hgb < 10 g/dL), and particularly high-risk cytogenetics (complex karyotype, monosomy 7). For a 63-year-old patient with high-risk disease, allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative option and the standard of care recommendation. While JAK inhibitors like ruxolitinib (Option B) are standard for managing splenomegaly and symptoms, Option B is incorrect because it explicitly suggests 'deferring further planning' until stabilization. In high-risk disease with adverse genetics, delaying transplant evaluation is clinically inappropriate. Option A is incorrect as the patient progressed on hydroxyurea and has anemia. Options D and E are not standard first-line management for this presentation. Therefore, Option C (transplant evaluation) is the unique best answer. The question is logically sound and medically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-003", "question": "A 28-year-old G1P0 woman at 33 weeks' gestation presents to the ED with acute dyspnea, pleuritic chest pain, and near syncope. HR 132/min, BP 82/48 mm Hg, RR 30/min, SpO2 89% on 6 L nasal cannula. Bedside echo reveals a dilated RV with McConnell sign and septal flattening. CTA is unavailable; lower-extremity duplex is pending. She is consentable and has no contraindications to thrombolysis. Fetal heart tones are 150 bpm with moderate variability. Which management is most appropriate now?", "options": ["Systemic thrombolysis with weight-based alteplase bolus and infusion", "Urgent catheter-directed thrombolysis with reduced-dose alteplase", "Immediate transfer for surgical embolectomy with cardiopulmonary bypass", "Initiate high-dose unfractionated heparin and defer reperfusion until postpartum", "Administer tenecteplase as a single IV bolus followed by heparin"], "answer": "A", "answer_index": 0, "explanation": "She has high-risk (massive) pulmonary embolism with shock in late pregnancy; systemic thrombolysis is recommended when no absolute contraindications exist, as maternal survival takes priority and pregnancy is only a relative contraindication. Catheter-directed therapy or surgical embolectomy may be considered when thrombolysis is contraindicated or fails, not as first-line; deferring reperfusion is unsafe, and tenecteplase bolus lacks robust pregnancy-specific safety and dosing data compared with standard alteplase protocols.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a pregnant patient with massive (high-risk) pulmonary embolism, evidenced by hypotension (shock), hypoxia, and echocardiographic signs of right ventricular failure (McConnell sign). In high-risk PE, immediate reperfusion is critical for maternal survival. Anticoagulation alone (Option D) is insufficient for shock. Transfer for surgery (Option C) is unsafe due to hemodynamic instability. While catheter-directed thrombolysis (Option B) is a valid consideration to minimize bleeding risk, it requires immediate specialized availability and time to set up; in a patient with frank shock (BP 82/48) and limited diagnostics (CTA unavailable), systemic thrombolysis (Option A) is the standard, most rapidly deployable life-saving intervention supported by guidelines (e.g., ESC, AHA). Alteplase is preferred over tenecteplase (Option E) in pregnancy due to more robust data. The item is logically sound, presenting a clear indication for thrombolysis where maternal life takes priority.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a pregnant patient with massive (high-risk) pulmonary embolism, evidenced by hypotension (shock), hypoxia, and echocardiographic signs of right ventricular failure (McConnell sign). In high-risk PE, immediate reperfusion is critical for maternal survival. Anticoagulation alone (Option D) is insufficient for shock. Transfer for surgery (Option C) is unsafe due to hemodynamic instability. While catheter-directed thrombolysis (Option B) is a valid consideration to minimize bleeding risk, it requires immediate specialized availability and time to set up; in a patient with frank shock (BP 82/48) and limited diagnostics (CTA unavailable), systemic thrombolysis (Option A) is the standard, most rapidly deployable life-saving intervention supported by guidelines (e.g., ESC, AHA). Alteplase is preferred over tenecteplase (Option E) in pregnancy due to more robust data. The item is logically sound, presenting a clear indication for thrombolysis where maternal life takes priority.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-004", "question": "A 4-year-old boy is brought to the PICU with progressive leg weakness and refusal to walk for 5 days after a viral upper respiratory infection. Exam: flaccid symmetric weakness in legs > arms, areflexia, intact sensation, no bowel/bladder dysfunction, and no cranial nerve involvement. He can lift his head briefly but cannot stand; FVC is 55% predicted. MRI spine is normal. CSF shows protein 42 mg/dL, 3 WBC/µL. Nerve conduction studies show reduced CMAP amplitudes with preserved conduction velocities and distal latencies; sensory studies are normal, and F-waves are absent. Which subtype best describes his neuropathy and has implications for prognosis and treatment response?", "options": ["Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)", "Acute motor axonal neuropathy (AMAN) variant of Guillain-Barré syndrome", "Acute motor and sensory axonal neuropathy (AMSAN)", "Miller Fisher syndrome", "Acute flaccid myelitis related to enterovirus D68"], "answer": "B", "answer_index": 1, "explanation": "Normal conduction velocities with low CMAP amplitudes, preserved sensory responses, and absent F-waves indicate a purely motor axonal process, characteristic of AMAN, which in children often follows infection and may have rapid progression but good recovery with immunotherapy. AIDP would show demyelinating features (slowed velocities, prolonged latencies), AMSAN would have sensory involvement, Miller Fisher presents with ophthalmoplegia/ataxia, and acute flaccid myelitis involves spinal gray matter with MRI abnormalities and asymmetric weakness.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The question describes a pediatric patient with acute flaccid paralysis and areflexia, consistent with Guillain-Barré Syndrome (GBS). The key to answering the question lies in the electrodiagnostic findings provided. The Nerve Conduction Studies (NCS) show reduced CMAP amplitudes (axonal loss or distal block) with preserved conduction velocities and distal latencies (ruling out primary demyelination), alongside normal sensory studies. This pattern is the textbook definition of Acute Motor Axonal Neuropathy (AMAN), making Option B the correct answer. Option A (AIDP) is incorrect because it requires demyelinating features (slowed velocities, prolonged latencies). Option C (AMSAN) is incorrect because sensory nerves are spared. Option D (Miller Fisher) is incorrect due to the absence of ophthalmoplegia and ataxia. Option E (Acute Flaccid Myelitis) is incorrect due to the symmetric nature of the weakness and the normal spinal MRI (AFM typically shows gray matter lesions). The item is logically sound, medically accurate, and the distractors are clearly excluded by the provided data.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The question describes a pediatric patient with acute flaccid paralysis and areflexia, consistent with Guillain-Barré Syndrome (GBS). The key to answering the question lies in the electrodiagnostic findings provided. The Nerve Conduction Studies (NCS) show reduced CMAP amplitudes (axonal loss or distal block) with preserved conduction velocities and distal latencies (ruling out primary demyelination), alongside normal sensory studies. This pattern is the textbook definition of Acute Motor Axonal Neuropathy (AMAN), making Option B the correct answer. Option A (AIDP) is incorrect because it requires demyelinating features (slowed velocities, prolonged latencies). Option C (AMSAN) is incorrect because sensory nerves are spared. Option D (Miller Fisher) is incorrect due to the absence of ophthalmoplegia and ataxia. Option E (Acute Flaccid Myelitis) is incorrect due to the symmetric nature of the weakness and the normal spinal MRI (AFM typically shows gray matter lesions). The item is logically sound, medically accurate, and the distractors are clearly excluded by the provided data.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-005", "question": "A 47-year-old man with poorly controlled type 2 diabetes and daily alcohol use presents with 10 days of fever, right-sided headache, and progressive confusion. He was treated with oral amoxicillin-clavulanate for presumed sinusitis without improvement. On exam he is disoriented, febrile (38.8°C), with mild left hemiparesis and papilledema. CT head with contrast shows a 3.5-cm ring-enhancing lesion in the right frontal lobe with extensive surrounding edema contiguous with opacified frontal sinus. Emergent dexamethasone and broad-spectrum IV antibiotics are started. Neurocritical care team plans operative management. Which surgical approach is most appropriate now?", "options": ["CT-guided stereotactic needle aspiration of the abscess", "Open craniotomy with complete abscess excision and sinus drainage", "Endoscopic transnasal drainage of the frontal sinus only", "Placement of an external ventricular drain for CSF diversion and observation", "Delay surgical intervention; continue maximal medical therapy for 2 weeks"], "answer": "B", "answer_index": 1, "explanation": "A large frontal lobe abscess contiguous with frontal sinus and mass effect in an immunocompromised host favors open craniotomy with abscess excision plus definitive sinus drainage to eradicate the source and relieve mass effect. Needle aspiration alone risks persistent infection from ongoing sinus seeding; sinus drainage only is insufficient; EVD does not address the mass; delaying surgery risks herniation and neurological decline.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). Verdict: Correct best answer. The vignette describes a large (3.5 cm) frontal brain abscess with significant mass effect (papilledema, hemiparesis) and a contiguous source (frontal sinusitis) in an immunocompromised patient. Standard neurosurgical indications for craniotomy with excision (over simple needle aspiration) include superficial location, large size (>2.5 cm), and specifically, abscesses resulting from contiguous spread (sinusitis) to allow for debridement of osteomyelitic bone, sinus drainage, and repair of dural defects to prevent recurrence. Option B correctly combines abscess excision with source control. Option A (aspiration) is less optimal as it fails to address the sinus source/dural defect definitively and may be insufficient for a lesion of this size with significant mass effect. Options C, D, and E are clinically inappropriate (insufficient treatment or dangerous delay). The item is medically accurate and logically sound.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict: Correct best answer. The vignette describes a large (3.5 cm) frontal brain abscess with significant mass effect (papilledema, hemiparesis) and a contiguous source (frontal sinusitis) in an immunocompromised patient. Standard neurosurgical indications for craniotomy with excision (over simple needle aspiration) include superficial location, large size (>2.5 cm), and specifically, abscesses resulting from contiguous spread (sinusitis) to allow for debridement of osteomyelitic bone, sinus drainage, and repair of dural defects to prevent recurrence. Option B correctly combines abscess excision with source control. Option A (aspiration) is less optimal as it fails to address the sinus source/dural defect definitively and may be insufficient for a lesion of this size with significant mass effect. Options C, D, and E are clinically inappropriate (insufficient treatment or dangerous delay). The item is medically accurate and logically sound.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-006", "question": "A 66-year-old man with COPD and metastatic non-small cell lung cancer (PD-L1 80%) started pembrolizumab 10 weeks ago. He presents with 4 days of worsening exertional dyspnea and dry cough, afebrile, with O2 saturation 90% on room air. CT pulmonary angiography shows no embolus but reveals new bilateral, patchy ground-glass opacities and reticular changes in the lower lobes with subpleural sparing. There is no infection on extensive workup, BNP is normal, and no cardiac ischemia. He is on no new drugs besides pembrolizumab. How should this complication be graded and managed now?", "options": ["Grade 1 pneumonitis; continue pembrolizumab with close monitoring only", "Grade 2 pneumonitis; hold pembrolizumab and start prednisone 0.5 mg/kg/day", "Grade 2 pneumonitis; hold pembrolizumab and start prednisone 1-2 mg/kg/day", "Grade 3 pneumonitis; permanently discontinue pembrolizumab and give IV methylprednisolone 1-2 mg/kg/day", "Grade 3 pneumonitis; permanently discontinue pembrolizumab and give infliximab immediately without steroids"], "answer": "C", "answer_index": 2, "explanation": "He has symptomatic but non-life-threatening immune-related pneumonitis (dyspnea, new infiltrates, no severe hypoxia), corresponding to grade 2; standard management is to hold the checkpoint inhibitor and start systemic steroids at 1-2 mg/kg/day with a prolonged taper. Grade 3 would involve severe symptoms or oxygen requirement; lower steroid doses or continuation of pembrolizumab are inadequate, and infliximab is reserved for steroid-refractory cases, not first-line.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a patient with immune checkpoint inhibitor (ICI)-related pneumonitis. The critical task is grading the severity to determine management. Grade 2 pneumonitis is defined as symptomatic (dyspnea, cough) limiting instrumental ADLs, whereas Grade 3 involves severe symptoms limiting self-care ADLs or requiring new supplemental oxygen. The patient presents with 'exertional' dyspnea (implying Grade 2 functional limitation) and an O2 saturation of 90% on room air. While 90% is borderline, the absence of an explicit oxygen requirement or dyspnea at rest favors Grade 2 over Grade 3 in a board-exam context. Current guidelines (ASCO/NCCN) for Grade 2 pneumonitis recommend holding the ICI and initiating systemic corticosteroids (prednisone 1–2 mg/kg/day). Option C correctly identifies the grade and the standard-of-care management. Option D (Grade 3) implies a higher severity requiring permanent discontinuation and IV steroids, which is not fully supported by the 'exertional' nature of symptoms. Option B proposes an sub-therapeutic steroid dose (0.5 mg/kg). The item is medically accurate and logically sound.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a patient with immune checkpoint inhibitor (ICI)-related pneumonitis. The critical task is grading the severity to determine management. Grade 2 pneumonitis is defined as symptomatic (dyspnea, cough) limiting instrumental ADLs, whereas Grade 3 involves severe symptoms limiting self-care ADLs or requiring new supplemental oxygen. The patient presents with 'exertional' dyspnea (implying Grade 2 functional limitation) and an O2 saturation of 90% on room air. While 90% is borderline, the absence of an explicit oxygen requirement or dyspnea at rest favors Grade 2 over Grade 3 in a board-exam context. Current guidelines (ASCO/NCCN) for Grade 2 pneumonitis recommend holding the ICI and initiating systemic corticosteroids (prednisone 1–2 mg/kg/day). Option C correctly identifies the grade and the standard-of-care management. Option D (Grade 3) implies a higher severity requiring permanent discontinuation and IV steroids, which is not fully supported by the 'exertional' nature of symptoms. Option B proposes an sub-therapeutic steroid dose (0.5 mg/kg). The item is medically accurate and logically sound.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-007", "question": "A 9-year-old girl presents with 2 weeks of progressive headache, morning vomiting, and decline in school performance. Exam reveals papilledema, dysmetria, and truncal ataxia. MRI brain shows an enhancing midline posterior fossa mass infiltrating the cerebellar vermis and roof of the fourth ventricle, with obstructive hydrocephalus. After CSF diversion and near-total resection, histology shows small round blue cells with Homer-Wright rosettes. Molecular profiling reveals WNT-activated medulloblastoma, CTNNB1 mutation, and monosomy 6; no metastatic disease on staging. Which adjuvant treatment strategy is most appropriate?", "options": ["Craniospinal irradiation at standard dose plus multi-agent chemotherapy (high-risk protocol)", "Focal posterior fossa irradiation only plus maintenance oral temozolomide", "Reduced-dose craniospinal irradiation with posterior fossa boost plus chemotherapy (standard-risk protocol)", "Observation only after gross total resection due to favorable WNT subtype", "High-dose chemotherapy with autologous stem cell rescue, without craniospinal irradiation"], "answer": "C", "answer_index": 2, "explanation": "WNT-activated medulloblastoma in a child with non-metastatic disease and near-total resection is standard-risk; current practice uses reduced-dose craniospinal irradiation with posterior fossa boost plus multi-agent chemotherapy to maintain excellent survival while reducing late toxicity. Standard-dose/high-risk protocols are unnecessary; focal RT alone or observation is inadequate due to CSF dissemination risk; high-dose chemo without CSI is investigational and not standard in this scenario.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a 9-year-old with WNT-activated medulloblastoma, non-metastatic (M0) disease, and near-total resection. Based on current risk stratification (Chang staging and molecular profiling), this patient falls into the 'standard-risk' (or average-risk) category. The standard of care for children >3 years old with standard-risk medulloblastoma is maximal safe resection followed by reduced-dose craniospinal irradiation (23.4 Gy) with a boost to the posterior fossa (or tumor bed) and adjuvant multi-agent chemotherapy. Standard-dose CSI (36 Gy) is reserved for high-risk disease (metastatic or subtotal resection). Focal irradiation alone (Option B) is contraindicated in medulloblastoma due to the risk of leptomeningeal spread. Observation (Option D) is unsafe as recurrence is nearly universal without adjuvant therapy. High-dose chemotherapy with stem cell rescue (Option E) is primarily used in infants (<3 years) to avoid radiation or in recurrent settings. Therefore, Option C is the unique, medically accurate best answer supported by major cooperative group trials (e.g., COG ACNS0331).\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a 9-year-old with WNT-activated medulloblastoma, non-metastatic (M0) disease, and near-total resection. Based on current risk stratification (Chang staging and molecular profiling), this patient falls into the 'standard-risk' (or average-risk) category. The standard of care for children >3 years old with standard-risk medulloblastoma is maximal safe resection followed by reduced-dose craniospinal irradiation (23.4 Gy) with a boost to the posterior fossa (or tumor bed) and adjuvant multi-agent chemotherapy. Standard-dose CSI (36 Gy) is reserved for high-risk disease (metastatic or subtotal resection). Focal irradiation alone (Option B) is contraindicated in medulloblastoma due to the risk of leptomeningeal spread. Observation (Option D) is unsafe as recurrence is nearly universal without adjuvant therapy. High-dose chemotherapy with stem cell rescue (Option E) is primarily used in infants (<3 years) to avoid radiation or in recurrent settings. Therefore, Option C is the unique, medically accurate best answer supported by major cooperative group trials (e.g., COG ACNS0331).", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-008", "question": "A 71-year-old woman with hypertension and atrial fibrillation on rivaroxaban is admitted with sudden onset aphasia and right hemiplegia. CT head is negative for hemorrhage; CTA shows left M1 occlusion. Last rivaroxaban dose was 3 hours ago. Labs: creatinine 0.9 mg/dL, normal platelets, INR 1.2, anti-factor Xa level (rivaroxaban-calibrated) 170 ng/mL. She arrives 70 minutes after symptom onset. You are in a center with neurointerventional capability and access to andexanet alfa and 4-factor PCC. What is the best acute reperfusion strategy?", "options": ["Administer IV alteplase followed by mechanical thrombectomy", "Administer andexanet alfa to reverse rivaroxaban, then give IV alteplase", "Proceed directly to mechanical thrombectomy without IV thrombolysis", "Give 4-factor PCC then IV alteplase to offset rivaroxaban effect", "Defer reperfusion therapy and manage with permissive hypertension alone"], "answer": "C", "answer_index": 2, "explanation": "Recent rivaroxaban ingestion with high anti-factor Xa level is a contraindication to IV alteplase, and reversal with andexanet or PCC before tPA is not recommended due to uncertain safety and lack of evidence. In patients with large-vessel occlusion on DOACs, direct mechanical thrombectomy is the preferred reperfusion strategy. Withholding reperfusion altogether is inappropriate given eligibility for thrombectomy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). Verdict: Correct best answer. The vignette describes a patient with an acute ischemic stroke due to a large vessel occlusion (Left M1) who is currently anticoagulated with rivaroxaban (last dose 3 hours ago, confirmed by elevated anti-factor Xa levels). Under current AHA/ASA guidelines, IV alteplase is contraindicated due to the active anticoagulant effect (DOAC taken < 48 hours with abnormal labs). Reversing the DOAC (with andexanet alfa or PCC) solely to administer IV alteplase is not recommended due to unproven benefit and potential risks. Since the patient has an LVO and is within the window for endovascular therapy, proceeding directly to mechanical thrombectomy is the standard of care. The item accurately tests the contraindications for thrombolysis and the indications for thrombectomy in anticoagulated patients. The distractors represent common management errors (giving tPA despite contraindication, unnecessary reversal) or negligence (deferring therapy).\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict: Correct best answer. The vignette describes a patient with an acute ischemic stroke due to a large vessel occlusion (Left M1) who is currently anticoagulated with rivaroxaban (last dose 3 hours ago, confirmed by elevated anti-factor Xa levels). Under current AHA/ASA guidelines, IV alteplase is contraindicated due to the active anticoagulant effect (DOAC taken < 48 hours with abnormal labs). Reversing the DOAC (with andexanet alfa or PCC) solely to administer IV alteplase is not recommended due to unproven benefit and potential risks. Since the patient has an LVO and is within the window for endovascular therapy, proceeding directly to mechanical thrombectomy is the standard of care. The item accurately tests the contraindications for thrombolysis and the indications for thrombectomy in anticoagulated patients. The distractors represent common management errors (giving tPA despite contraindication, unnecessary reversal) or negligence (deferring therapy).", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-009", "question": "A 22-year-old man with sickle cell disease (HbSS) presents with high fever, cough, and pleuritic chest pain. CXR shows new multilobar infiltrates; oxygen saturation is 93% on 2 L/min nasal cannula. Labs: Hgb 7.2 g/dL (baseline 8.5), WBC 18,000/µL, platelets 310,000/µL, reticulocyte count 12%. He is diagnosed with acute chest syndrome and started on broad-spectrum antibiotics, incentive spirometry, and simple transfusion to Hgb 9.5 g/dL. Over 24 hours, oxygen requirement increases to 8 L/min with SpO2 90%, and CXR shows progression to near-complete bilateral airspace opacification. Hgb is now 10.3 g/dL, and he is tachypneic but not yet intubated. Which is the most appropriate next step?", "options": ["Increase simple transfusions to target Hgb 12 g/dL for better oxygen-carrying capacity", "Initiate exchange transfusion targeting HbS <30%", "Start high-dose corticosteroids to reduce pulmonary inflammation", "Add therapeutic anticoagulation for presumed pulmonary embolism", "Intubate and initiate low tidal-volume ventilation, deferring transfusion changes"], "answer": "B", "answer_index": 1, "explanation": "Worsening hypoxemia, radiographic progression, and clinical deterioration despite initial simple transfusion indicate severe acute chest syndrome, for which exchange transfusion to rapidly lower HbS (<30%) is recommended. Further simple transfusion risks hyperviscosity; steroids are controversial and may increase rebound pain; empiric anticoagulation is not first-line without PE evidence; ventilation may be needed but does not replace disease-modifying exchange.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The vignette describes a patient with Sickle Cell Disease (HbSS) suffering from severe Acute Chest Syndrome (ACS) that is progressing despite initial simple transfusion and supportive care. Key indicators of severity include multilobar infiltrates, worsening hypoxia (requiring 8 L/min), and clinical deterioration. Current guidelines (e.g., ASH 2020) recommend red cell exchange transfusion (erythrocytapheresis) for severe ACS to rapidly lower HbS levels (<30%) while avoiding hyperviscosity. Option B is the correct best answer. Option A is contraindicated; increasing Hgb >10–11 g/dL increases blood viscosity and can worsen vaso-occlusion. Option C (steroids) is controversial due to high rates of rebound pain/readmission and is not the standard rescue therapy. Option D is incorrect as ACS is the established diagnosis; while PE is a differential, empiric therapeutic anticoagulation is not the priority over exchange transfusion. Option E (intubation) is a supportive measure for respiratory failure but does not treat the underlying pathophysiology; exchange transfusion is the necessary disease-modifying intervention. The item is logically valid and medically accurate.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The vignette describes a patient with Sickle Cell Disease (HbSS) suffering from severe Acute Chest Syndrome (ACS) that is progressing despite initial simple transfusion and supportive care. Key indicators of severity include multilobar infiltrates, worsening hypoxia (requiring 8 L/min), and clinical deterioration. Current guidelines (e.g., ASH 2020) recommend red cell exchange transfusion (erythrocytapheresis) for severe ACS to rapidly lower HbS levels (<30%) while avoiding hyperviscosity. Option B is the correct best answer. Option A is contraindicated; increasing Hgb >10–11 g/dL increases blood viscosity and can worsen vaso-occlusion. Option C (steroids) is controversial due to high rates of rebound pain/readmission and is not the standard rescue therapy. Option D is incorrect as ACS is the established diagnosis; while PE is a differential, empiric therapeutic anticoagulation is not the priority over exchange transfusion. Option E (intubation) is a supportive measure for respiratory failure but does not treat the underlying pathophysiology; exchange transfusion is the necessary disease-modifying intervention. The item is logically valid and medically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-010", "question": "A 58-year-old man with alcohol-related cirrhosis and portal hypertension is admitted with confusion and generalized tonic-clonic seizures. He has been on valproic acid for epilepsy for 5 years without prior complications. Medications include lactulose and spironolactone. Exam: asterixis, disorientation, jaundice, and mild ascites. Labs: Na 130 mmol/L, K 4.2 mmol/L, BUN 10 mg/dL, creatinine 0.7 mg/dL, AST 65 U/L, ALT 40 U/L, total bilirubin 3.8 mg/dL, INR 1.7, ammonia 96 µmol/L. Serum valproate level is therapeutic, but free valproate level is supratherapeutic; serum carnitine is low, and EEG shows triphasic waves without epileptiform activity. Which is the most appropriate antiseizure management strategy?", "options": ["Continue valproic acid but lower the dose and optimize lactulose therapy", "Discontinue valproic acid and start levetiracetam with IV L-carnitine supplementation", "Switch valproic acid to phenytoin with aggressive albumin replacement", "Add topiramate to valproic acid to improve seizure control", "Continue valproic acid and start rifaximin to reduce ammonia"], "answer": "B", "answer_index": 1, "explanation": "He has cirrhosis with hyperammonemic encephalopathy and high free valproate, consistent with valproate-induced hyperammonemic encephalopathy exacerbated by liver disease and carnitine deficiency; the best approach is to stop valproate, use a non-hepatically metabolized agent such as levetiracetam, and give IV L-carnitine. Dose reduction or adjuncts (lactulose, rifaximin) without discontinuing valproate will not adequately address toxicity; phenytoin is highly protein-bound and hepatically metabolized, and adding topiramate may worsen hyperammonemia.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The patient presents with classic signs of valproate-induced hyperammonemic encephalopathy (VHE) in the setting of cirrhosis. Key diagnostic clues include the elevated ammonia, supratherapeutic free valproate levels (despite therapeutic total levels, common in hypoalbuminemia), low serum carnitine, and EEG findings of metabolic encephalopathy (triphasic waves). Valproic acid inhibits the urea cycle and depletes carnitine, worsening hyperammonemia, which is particularly dangerous in patients with pre-existing liver disease. The definitive management is to discontinue the offending agent, replenish carnitine, and switch to a seizure medication that is safe in hepatic failure. Option B is the correct best answer: Levetiracetam is the preferred agent in cirrhosis as it is renally cleared, has no hepatic metabolism, and minimal protein binding. IV L-carnitine is the specific antidote for VHE. Options A and E are incorrect because continuing valproate perpetuates the metabolic toxicity regardless of gut-ammonia therapies (lactulose/rifaximin). Option C is suboptimal because phenytoin is hepatically metabolized and highly protein-bound, leading to unpredictable kinetics in cirrhosis. Option D is contraindicated as topiramate can synergistically worsen hyperammonemia. The item is logically valid and medically accurate.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The patient presents with classic signs of valproate-induced hyperammonemic encephalopathy (VHE) in the setting of cirrhosis. Key diagnostic clues include the elevated ammonia, supratherapeutic free valproate levels (despite therapeutic total levels, common in hypoalbuminemia), low serum carnitine, and EEG findings of metabolic encephalopathy (triphasic waves). Valproic acid inhibits the urea cycle and depletes carnitine, worsening hyperammonemia, which is particularly dangerous in patients with pre-existing liver disease. The definitive management is to discontinue the offending agent, replenish carnitine, and switch to a seizure medication that is safe in hepatic failure. Option B is the correct best answer: Levetiracetam is the preferred agent in cirrhosis as it is renally cleared, has no hepatic metabolism, and minimal protein binding. IV L-carnitine is the specific antidote for VHE. Options A and E are incorrect because continuing valproate perpetuates the metabolic toxicity regardless of gut-ammonia therapies (lactulose/rifaximin). Option C is suboptimal because phenytoin is hepatically metabolized and highly protein-bound, leading to unpredictable kinetics in cirrhosis. Option D is contraindicated as topiramate can synergistically worsen hyperammonemia. The item is logically valid and medically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]